NDA 208700 · Aaa USA INC
Lutathera
Lutetium Lu-177 Dotatate · Intravenous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jan 26, 2018
Approved uses
5
Original approval plus efficacy supplements
Registered trials
72
13 Phase 3, 27 recruiting
FAERS reports
5,819
2,380 serious, 712 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 15, 2026.
LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.
Mechanism: Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 somatostatin receptors (SSTR2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta-minus emission from lutetium-177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 23, 2024 Supplement 31 · Efficacy · priority review OrphanLabel
- Jun 13, 2022 Supplement 19 · Efficacy OrphanLetterLabel
- May 29, 2020 Supplement 1 · Efficacy Label
- May 28, 2020 Supplement 10 · Efficacy OrphanLetter
- Jan 26, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- LUTATHERA · LUTETIUM LU-177 DOTATATE 10mCi/ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Lutetium Lu-177 Dotatate" as an intervention, any sponsor and status, largest first.
AHS Cancer Control AlbertaAcademic, hospital or other
NCT01876771 · 413 participants · Start Apr 29, 2014 · Primary completion Dec 2042
Drug: [177]Lu-DOTA-TATE · For: Carcinoma, Neuroendocrine
Sites: Edmonton, Canada
- Personalized PRRT of Neuroendocrine TumorsActive, not recruiting
CHU de Quebec-Universite LavalAcademic, hospital or other
NCT02754297 · 275 participants · Start Apr 12, 2016 · Primary completion Apr 12, 2025
Drug: 177Lu-Octreotate · For: Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Neuroendocrine
Sites: Québec, Canada
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06784752 · 240 participants (planned) · Start May 30, 2025 · Primary completion Dec 8, 2028
Drug: Octreotide LAR · For: Somatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Denver, Colorado · 67 sites in all
- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursPivotal-lookingCompleted
Advanced Accelerator ApplicationsNovartis (NVS)
NCT01578239 · 231 participants · Start Sep 6, 2012 · Primary completion Jul 31, 2015
Drug: Octreotide LAR; 177Lu-DOTA0-Tyr3-Octreotate · For: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Sites: Los Angeles, California; Palo Alto, California; Tampa, Florida · 39 sites in all
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETPivotal-lookingActive, not recruiting
Advanced Accelerator ApplicationsNovartis (NVS)
NCT03972488 · 226 participants · Start Jan 8, 2020 · Primary completion Jul 20, 2023
Drug: Lutathera; 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot) and 2 more · For: Gastro-enteropancreatic Neuroendocrine Tumor
Sites: New Haven, Connecticut; Tampa, Florida; Iowa City, Iowa · 40 sites in all
- An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Pivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05884255 · 220 participants (planned) · Start Jul 6, 2023 · Primary completion Dec 2026
Drug: Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide; long-acting Octreotide · For: Advanced Gastroenteropancreatic Neuroendocrine Tumor
Sites: Shanghai, China; Tianjin, China
- A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETsPivotal-lookingCompleted
Sinotau Pharmaceutical GroupIndustry
NCT05459844 · 196 participants · Start Aug 31, 2022 · Primary completion Jun 26, 2025
Drug: Lutetium[177Lu] Oxodotreotide Injection; Octreotide LAR · For: Neuroendocrine Tumors
Sites: Beijing, China; Fuzhou, China; Xiamen, China · 23 sites in all
University Health Network, TorontoAcademic, hospital or other
NCT02743741 · 195 participants · Start Jul 15, 2016 · Primary completion Aug 18, 2026
Drug: Lutetium-177 Octreotate · For: Neuroendocrine Tumors
Sites: Hamilton, Canada; London, Canada; Toronto, Canada · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ill-defined disorder1,542
- general physical health deterioration1,294
- death441
- malignant neoplasm progression364
- nausea236
- platelet count decreased231
- covid-19198
- fatigue193
- diarrhoea189
- disease progression174
- laboratory test abnormal174
- illness167
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2014 | 2 |
| 2017 | 2 |
| 2018 | 43 |
| 2019 | 102 |
| 2020 | 162 |
| 2021 | 1,352 |
| 2022 | 829 |
| 2023 | 1,015 |
| 2024 | 1,043 |
| 2025 | 832 |
| 2026 | 436 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R, Varley-Campbell J, Tikhonova I, et al. · Health Technol Assess 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung.
Kim C, Liu SV, Subramaniam DS, et al. · J Immunother Cancer 2020 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).
Deshayes E, Assenat E, Meignant L, et al. · BMC Cancer 2022 · Randomized Controlled Trial, Multicenter Study
Sponsor: Aaa USA INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.